UY36595A - COMPLEX PHARMACEUTICAL FORMULATION INCLUDING AMLODIPINA, LOSARTÁN AND CLORTALIDONA - Google Patents
COMPLEX PHARMACEUTICAL FORMULATION INCLUDING AMLODIPINA, LOSARTÁN AND CLORTALIDONAInfo
- Publication number
- UY36595A UY36595A UY0001036595A UY36595A UY36595A UY 36595 A UY36595 A UY 36595A UY 0001036595 A UY0001036595 A UY 0001036595A UY 36595 A UY36595 A UY 36595A UY 36595 A UY36595 A UY 36595A
- Authority
- UY
- Uruguay
- Prior art keywords
- pharmaceutical formulation
- chlorthalidone
- losartan
- amlodipine
- losartán
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
La presente invención proporciona una formulación compleja farmacéutica que comprende una primera mezcla que incluye amlodipina y clortalidona y una segunda mezcla que incluye losartán, que tiene disolución y estabilidad mejoradas. La formulación compleja de acuerdo con la presente invención puede alcanzar efectos preventivos o terapéuticos mejorados para enfermedades cardiovasculares accionando diferentes mecanismos de amlodipina, losartán y clortalidona, y muestra altas velocidades de disolución de amlodipina, losartán y clortalidona y estabilidad de almacenamiento mejorada, debido a las interacciones de fármaco minimizadas, y entonces, es útil en los campos de los medicamentos y la medicina.The present invention provides a complex pharmaceutical formulation comprising a first mixture that includes amlodipine and chlorthalidone and a second mixture that includes losartan, which has improved dissolution and stability. The complex formulation according to the present invention can achieve improved preventive or therapeutic effects for cardiovascular diseases by operating different mechanisms of amlodipine, losartan and chlorthalidone, and shows high dissolution rates of amlodipine, losartan and chlorthalidone and improved storage stability, due to the Minimized drug interactions, and then, is useful in the fields of medications and medicine.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150045645A KR101914930B1 (en) | 2015-03-31 | 2015-03-31 | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36595A true UY36595A (en) | 2016-10-31 |
Family
ID=57007292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036595A UY36595A (en) | 2015-03-31 | 2016-03-30 | COMPLEX PHARMACEUTICAL FORMULATION INCLUDING AMLODIPINA, LOSARTÁN AND CLORTALIDONA |
Country Status (11)
Country | Link |
---|---|
KR (1) | KR101914930B1 (en) |
CN (1) | CN108289850B (en) |
AR (1) | AR105758A1 (en) |
JO (1) | JO3461B1 (en) |
MX (1) | MX2017012459A (en) |
MY (1) | MY190016A (en) |
PH (1) | PH12017501769A1 (en) |
RU (1) | RU2713883C2 (en) |
TW (1) | TWI714560B (en) |
UY (1) | UY36595A (en) |
WO (1) | WO2016159535A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101910902B1 (en) * | 2016-11-03 | 2018-10-24 | 한미약품 주식회사 | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone |
KR20180053044A (en) * | 2016-11-11 | 2018-05-21 | 주식회사유한양행 | A pharmaceutical composition in a monolithic matrix tablet form comprising chlorthalidone or its salt and amlodipine or its salt and a process for preparing the same |
KR20200143914A (en) * | 2019-06-17 | 2020-12-28 | 주식회사유한양행 | A pharmaceutical composition in a multi-layered tablet form comprising amlodipine or its salt and chlorthalidone its salt |
KR20210074428A (en) | 2019-12-11 | 2021-06-22 | 한미약품 주식회사 | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone |
KR20210152943A (en) | 2020-06-09 | 2021-12-16 | 한미약품 주식회사 | Pharmaceutical combination preparation for the prevention or treatment of cardiovascular diseases including amlodipine, losartan and chlorthalidone in a single layer tablet |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5138069A (en) | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
WO1995017396A1 (en) | 1993-12-23 | 1995-06-29 | Merck & Co., Inc. | Polymorphs of losartan and the process for the preparation of form ii of losartan |
KR100452491B1 (en) | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | A novel crystalline amlodipine camsylate and a preparing method thereof |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
JP2009513543A (en) * | 2003-07-16 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Chlorthalidone combination |
US20070237815A1 (en) * | 2006-04-06 | 2007-10-11 | Lawrence Solomon | Dosage forms and methods comprising amlodipine and chlorthalidone |
KR101247583B1 (en) * | 2006-12-08 | 2013-03-26 | 한미사이언스 주식회사 | Pharmaceutical composition comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof |
KR20090057538A (en) * | 2007-12-03 | 2009-06-08 | 박사룡 | A composition for treating hypertension comprising angiotensin ii antagonist, calsium andtagonist and diuretics |
WO2009084040A1 (en) * | 2007-12-28 | 2009-07-09 | Rubicon Research Private Limited | Once a day formulation of angiotensin receptor blockers |
CA2749903C (en) | 2009-01-23 | 2016-09-06 | Jae Hyun Park | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
KR101907881B1 (en) * | 2011-12-30 | 2018-12-11 | 한미약품 주식회사 | Fixed dose combination formulation comprising losartan, amlodipine and hydrochlorothiazide |
KR101392364B1 (en) * | 2012-04-17 | 2014-05-07 | 한국유나이티드제약 주식회사 | Pharmaceutical composition comprising amlodipine and losartan having an improved stability |
-
2015
- 2015-03-31 KR KR1020150045645A patent/KR101914930B1/en active IP Right Grant
-
2016
- 2016-03-11 MY MYPI2017703447A patent/MY190016A/en unknown
- 2016-03-11 RU RU2017134562A patent/RU2713883C2/en active
- 2016-03-11 CN CN201680020057.5A patent/CN108289850B/en active Active
- 2016-03-11 WO PCT/KR2016/002437 patent/WO2016159535A1/en active Application Filing
- 2016-03-11 MX MX2017012459A patent/MX2017012459A/en unknown
- 2016-03-18 TW TW105108523A patent/TWI714560B/en not_active IP Right Cessation
- 2016-03-27 JO JOP/2016/0058A patent/JO3461B1/en active
- 2016-03-29 AR ARP160100825A patent/AR105758A1/en unknown
- 2016-03-30 UY UY0001036595A patent/UY36595A/en not_active Application Discontinuation
-
2017
- 2017-09-26 PH PH12017501769A patent/PH12017501769A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2017134562A3 (en) | 2019-08-15 |
PH12017501769B1 (en) | 2018-03-19 |
TWI714560B (en) | 2021-01-01 |
PH12017501769A1 (en) | 2018-03-19 |
TW201639563A (en) | 2016-11-16 |
WO2016159535A1 (en) | 2016-10-06 |
KR101914930B1 (en) | 2018-11-05 |
MY190016A (en) | 2022-03-22 |
CN108289850B (en) | 2021-04-09 |
CN108289850A (en) | 2018-07-17 |
MX2017012459A (en) | 2018-01-30 |
AR105758A1 (en) | 2017-11-08 |
RU2713883C2 (en) | 2020-02-10 |
KR20160117055A (en) | 2016-10-10 |
RU2017134562A (en) | 2019-04-04 |
JO3461B1 (en) | 2020-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36595A (en) | COMPLEX PHARMACEUTICAL FORMULATION INCLUDING AMLODIPINA, LOSARTÁN AND CLORTALIDONA | |
CL2017003459A1 (en) | Cyclic sulfamoylarylamide derivatives and their use as medicines for the treatment of hepatitis b. | |
DOP2016000071A (en) | BRUTON TYPEOSIN CINASE INHIBITORS | |
BR112018076601A2 (en) | oral pharmaceutical formulation, methods for treating a patient, and use of a formulation | |
BR112018010671A8 (en) | shape-changing drug delivery devices and methods | |
CU20170172A7 (en) | 4,6-DIAMINOQUINOLIN-3-CARBONITRILS SUBSTITUTED USEFUL AS ANALGESIC, ANTIPIRÉTIC OR ANTIINFLAMATORIOS AND ANTINEOPLÁSICOS AGENTS | |
NI201600115A (en) | SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B. | |
UY35907A (en) | NEW INDAZOLCARBOXAMIDS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
GT201500021A (en) | SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B | |
UY35210A (en) | AUTOTAXIN INHIBITORS | |
CL2018002727A1 (en) | Medicine obtained by combining agonist fxr and arb | |
GT201400059A (en) | DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
ECSP19038749A (en) | PHARMACEUTICAL COMPLEX FORMULATION INCLUDING AMLODIPINE, LOSARTAN AND CLORTALIDONE | |
SV2017005412A (en) | COMPOUNDS OF 1-RENT-6-OXO-1,6-DIHIDROPIRIDIN-3-ILO AND USES OF THE SAME | |
UY35455A (en) | TRIPEPTIDIC INHIBITORS OF PROTEASA EPOXYCETONE | |
DOP2016000254A (en) | PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE. | |
PE20150353A1 (en) | DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAENO 3-SUBSTITUTED, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
DOP2018000034A (en) | COMBINATIONS OF AN OX40 ANTIBODY AND A TLR4 MODULATOR AND USES OF THE SAME | |
EA201501164A1 (en) | SOLID PHARMACEUTICAL MEDICINE FORM | |
CO2022005082A2 (en) | Phxia inhibitors and preparation method thereof and pharmaceutical application thereof | |
BR112017010442A2 (en) | pharmaceutical product, uses a polymer syringe, oxygen sequestering compound, and immunoglobulin solution | |
CL2018000282A1 (en) | Selected amide of gamma-hydroxybutyric acid and uses thereof in the treatment of alcohol abuse | |
CO2021008962A2 (en) | Active Testosterone Ester Derivatives, Compositions and Uses Thereof | |
CL2018000085A1 (en) | Heteroaryl carbonitriles for the treatment of diseases | |
ECSP19040732A (en) | PREPARATION OF PHARMACEUTICAL COMPLEX INCLUDING AMLODIPINE, LOSARTAN AND ROSUVASTATIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20221104 |